Artios: Venture Capital Funding History

Artios

To add a bio or update company history, please click update information.

News from Artios

Artios Pharma lands £90m Series D led by SV Health Investors and RA Capital Management to advance DNA damage response therapeutics

18 Nov 2025

Artios Pharma lands £90m Series D led by SV Health Investors and RA Capital Management to advance DNA damage response therapeutics

Artios Pharma develops cancer treatments that target DNA damage response pathways, focusing on patient groups with limited existing treatment options.

Artios

Life Sciences
Cambridge, United Kingdom
£90m
artios.com
Update Information

More venture news

adsilico
26 Oct 2026
adsilico unlocks a £10m Series A round led by PXN Ventures for virtual testing of implantable medical devices
Series ALife Sciences
imphatec
26 Oct 2026
imphatec raises a £1.5m seed round led by SynBioVen to develop customisable-dose implants for chronic conditions
SeedLife Sciences
OMass Therapeutics
15 Oct 2026
OMass Therapeutics raises a £230m Series C round from VCs including Bain Capital to develop small molecule therapeutics with drug discovery platform
Series CLife Sciences

Artios: Venture Capital Funding History

News from Artios

Artios Pharma lands £90m Series D led by SV Health Investors and RA Capital Management to advance DNA damage response therapeutics

More venture news

adsilico unlocks a £10m Series A round led by PXN Ventures for virtual testing of implantable medical devices

imphatec raises a £1.5m seed round led by SynBioVen to develop customisable-dose implants for chronic conditions

OMass Therapeutics raises a £230m Series C round from VCs including Bain Capital to develop small molecule therapeutics with drug discovery platform